KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ, M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA and M. MOEHLER. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO OPEN. AMSTERDAM: ELSEVIER, 2022, vol. 7, No 2, p. 1-8. ISSN 2059-7029. Available from: https://dx.doi.org/10.1016/j.esmoop.2022.100392.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective
Authors KOESSLER, T. (guarantor), M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA and M. MOEHLER.
Edition ESMO OPEN, AMSTERDAM, ELSEVIER, 2022, 2059-7029.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 7.300
RIV identification code RIV/00216224:14110/22:00128331
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.esmoop.2022.100392
UT WoS 000819921700001
Keywords in English oesophagus cancer; stomach cancer; pancreatic cancer; neuroendocrine tumours; colorectal cancer
Tags 14110516, 14110811, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 27/1/2023 13:58.
Abstract
There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.
PrintDisplayed: 21/6/2024 14:37